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Inhibitors of the oncogenic Ras-MAPK pathway have
been intensely pursued as therapeutics. Targeting
this pathway, however, presents challenges due to
the essential role of MAPK in homeostatic functions.
The phosphorylation and activation of MAPK sub-
strates is regulated by protein-protein interactions
with MAPK docking sites [1, 2]. Active ERK1/2 (extra-
cellular signal-regulated kinase 1/2)-MAPKs localize
to effectors containing DEF (docking site for ERK,
F/Y -X-F/Y -P)- or D-domain (docking domain) motifs.
We have examined the in vivo activity of ERK2 mu-
tants with impaired ability to signal via either docking
site. Mutations in the DEF-domain binding pocket pre-
vent activation of DEF-domain-containing effectors
but not RSK (90 kDa ribosomal S6 kinase), which con-
tains a D domain. Conversely, mutation of the ERK2
CD domain, which interacts with D domains, prevents
RSK activation but not DEF-domain signaling. Uncou-
pling docking interactions does not compromise
ERK2 phosphotransferase activity. ERK2 DEF mu-
tants undergo regulated nuclear translocation but are
defective for Elk-1/TCF transactivation and target
gene induction. Thus, downstream branches of ERK2
signaling can be selectively inhibited without block-
ing total pathway activity. Significantly, several pro-
tooncogenes contain DEF domains and are regulated
by ERK1/2 [3]. Therefore, disrupting ERK-DEF domain
interactions could be an alternative to inhibiting on-
cogenic Ras-MAPK signaling.
Results and Discussion
Signal transduction networks use protein-protein in-
teractions, and spatial and temporal regulation, to gen-
erate signal specificity, which ultimately controls cellu-
lar behavior [2]. Within the ERK1/2-MAPK pathway,
docking sites provide the necessary localization infor-
mation to direct ERK1/2 to binding partners and sub-
strates. The DEF domain docking site is responsible for
recruitment of active ERK1/2 to IEG (immediate early
gene) targets during sustained signaling [3, 4]. Another
distinct docking site, the D domain, is required for acti-
vation of the ERK1/2 effector kinase RSK [5, 6] but may
also be important for ERK1/2 inactivation by phospha-
tases [7]. We sought to determine if signaling to either*Correspondence: jblenis@hms.harvard.edu
2These authors made equal contributions.docking site could be functionally separated. In vitro,
a DEF domain peptide inhibited the ability of ERK2 to
phosphorylate c-Fos in a concentration-dependent
manner (Figure 1A) consistent with the presence of a
DEF domain in c-Fos [4]. In contrast, a D-domain pep-
tide was a less-potent inhibitor of c-Fos phosphoryla-
tion (Figure 1A). Thus, ERK signaling to DEF domains
and D domains can be functionally separated without
grossly affecting total kinase activity. Recently, specific
residues on ERK2 (e.g., L198, L232, or Y261) have been
proposed to interact with DEF domains in vitro [8] but
have not been examined in vivo. Interactions with D
domains are mediated by D316 and D319 in the ERK2
CD domain [9]. Various ERK2 point mutants were pre-
pared and initially analyzed for their ability to phospho-
rylate a D-domain substrate (RSK) or a DEF-domain
substrate (c-Fos) in vitro. Although alanine substitu-
tions at L198, L232, or Y261 had little effect on the
ability of ERK2 to phosphorylate RSK (Figure 1B),
phosphotransferase activity toward c-Fos was signifi-
cantly inhibited (Figure 1C). Similar to the single point
mutants, double alanine substitution at L198 and L232,
ERK2-L198/232A, exhibited activity toward RSK but not
c-Fos (data not shown). Conversely, substitution of
D319 with asparagine (D319N) prevented ERK2 from
phosphorylating RSK (Figure 1B) but had little effect on
c-Fos phosphorylation (Figure 1C). Relative initial
velocity measurements of ERK2-Y261A and -D319N to-
ward RSK or Fos substrates further confirmed that
these mutants retain wild-type levels of intrinsic en-
zyme activity (Figures S1A and S1B in the Supplemen-
tal Data available with this article online).
Activation-loop TEY phosphorylation in each mutant
was similar to wild-type ERK2, indicating that these
mutations do not interfere with the regulated activation
of ERK2 in vivo (Figures 1B and 1C). This observation
is of interest because MEK-mediated cytoplasmic re-
tention of ERK in quiescent cells and subsequent acti-
vation during the G0/G1 transition requires MEK-ERK
interaction. Our data are consistent with previous evi-
dence suggesting that this interaction is multivalent
[10]. Thus, ERK substrate docking can be selectively
dissociated in vitro by single point mutations without
perturbing ERK activation or intrinsic catalytic activity.
Because substrate targeting is an essential aspect
of ERK1/2 signaling, we studied the ability of specific
docking-defective ERK2 proteins to signal to represen-
tative effectors in vivo. The regulation of T325 phos-
phorylation in c-Fos requires ERK docking with a DEF
domain [4]. Quantitation of overexpressed ERK2 signal-
ing in cells, either wild-type, DEF-domain docking mu-
tants (L232A or Y261A) or a D-domain docking mutant
(D319N), confirmed the relative difference in target
phosphorylation demonstrated in vitro (Figure S1C).
RNA interference (RNAi) was used to downregulate en-
dogenous ERK1/2 and thereby inhibit the phosphoryla-
tion of c-Fos T325 and Elk-1 S383, both DEF-domain-
dependent phosphorylation events [4, 11] (Figure S1D).
Reexpression of rat ERK2 in siRNA-transfected cells
completely restored target phosphorylation (Figure 2A,
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1320Figure 1. Inhibiting ERK Substrate Phosphorylation without Reduc-
ing Total ERK Kinase Activity
(A) ERK2-mediated phosphorylation of c-Fos in the presence and
absence of synthetic peptides containing a DEF domain (DEF), a
mutated DEF domain (mut DEF), or a D domain. Data shown are
the mean ± SEM from two independent experiments.
(B) D-domain-dependent substrate phosphorylation was measured
with GST-RSK as a substrate. The indicated HA-ERK2 mutants
were expressed in NIH 3T3 cells, immunoprecipitated, and then
used in kinase reactions. The quantitation is representative of three
independent experiments. Levels of phosphorylated HA-ERK2 in
each kinase reaction are shown in the pERK and ERK Western
blots. Note that the small reduction in phosphorylated ERK2-L198A
F
(is due to reduced levels of HA-ERK2 in the precipitate.
d(C) DEF-domain-dependent substrate phosphorylation was mea-
isured with His6-c-FosEE as a substrate and performed as in (B).
s
tigure 2. Inhibition of ERK2 Signaling to DEF Domains In Vivo
A) ERK2 signaling to DEF domains in vivo was revealed by first
ownregulating endogenous ERK1/2 by siRNA and then reexpress-
ng either wild-type HA-ERK2 or the indicated mutants as de-
cribed in the Experimental Procedures. The phosphorylation of
ransfected c-Fos and endogenous Elk-1 was measured with phos-
phospecific antibodies.
(B) Cells were transfected with ERK1/2 siRNAs and the indicated
HA-ERK2 mutants, serum starved, and then treated with EGF for
5 min to induce nuclear translocation. Stimulated cells were then
processed for indirect immunofluorescence with anti-HA antibod-
ies. Data shown are identical to observations made from three in-
dependent experiments.Figure S1D). In contrast, reexpression of ERK2-L232A
or -Y261A had a significantly reduced effect on c-Fos
and Elk-1 phosphorylation, indicating that these resi-
dues are required for DEF-domain signaling in vivo (Fig-
ure 2A). Importantly, ERK2-D319N rescued c-Fos and
Elk-1 phosphorylation in vivo (Figure 2A).
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directly affected signaling to DEF domains (Figure 1C).
However, loss of signaling to DEF domains in vivo could
also result from aberrant localization of ERK. The exact
mechanism regulating ERK1/2 nuclear translocation re-
mains unclear. Data supporting both an active and pas-
sive process [12–14], as well as a role for ERK binding
to DEF domain-like FXFG motifs found in nucleoporin
proteins [14, 15], exist. To decrease the potential for
HA-ERK dimerization with endogenous ERK1/2 to con-
tribute to nuclear translocation [13, 16], indirect immu-
nofluorescence was performed on cells transfected
with ERK1/2 siRNAs (Figure S2A). In HeLa cells, nuclear
translocation of ERK2 occurs within minutes of growth-
factor stimulation [17](Figure S2B). Under identical con-
ditions, EGF-regulated nuclear accumulation of ERK2
was not significantly altered by mutations in the DEF-
domain binding pocket (Figure 2B). Consistent with
previous findings [18], mutation of D319 did not inhibit
nuclear translocation (Figure 2B) but reduced cytoplas-
mic retention in serum-deprived cells (data not shown).
Importantly, ERK2-L198A/L232A, which is defective for
nup153 binding in vitro [8], underwent EGF-dependent
nuclear translocation similarly to ERK2-wt (Figure 2B),
suggesting that nuclear import of ERK2 can take place
independently of FXFG interactions.
To show that the ERK2 mutants defective for DEF-
domain signaling (Figures 1C and 2A) can still signal to
other targets, we examined RSK activation. Mutations
in the DEF-domain binding pocket did not prevent
ERK2 from regulating the phosphorylation of avian RSK
T590. Importantly, the CD-domain mutation D319N did
(Figure 3A). Whereas downregulation of endogenous
ERK1/2 with RNAi inhibited RSK activation (Figure 3A,
bar chart), this defect was fully rescued with ERK2-wt
or ERK2-Y261A. Re-expression of ERK2-D319N, how-
ever, restored activity to only 40% of the control (Figure
3A; also Figure S2C). ERK2-L232A also restored RSK
activity more than ERK2-D319N.
After nuclear translocation, activated ERK1 and
ERK2 dock to and activate the Ets family transcription
factor Elk-1 [19], leading to induction of specific IEGs.
Consistent with the presence of a DEF domain in Elk-1
[11], mutations of L198, L232, or Y261 in ERK2 virtually
inhibited all ERK2-mediated Elk-1 transactivation (Fig-
ure 3B). Furthermore, ERK2-D319N consistently in-
duced Elk-1 transactivation more than wild-type ERK
(Figure 3B), perhaps as a result of decreased cytoplas-
mic retention and/or phosphatase-mediated inacti-
vation. These data suggest that DEF-domain, but not
D-domain, interactions are likely critical for Elk-1-medi-
ated IEG induction. To test this hypothesis, we exam-
ined induction of the egr-1 (early growth response pro-
tein 1) IEG. RNAi-mediated downregulation of ERK1/2
inhibited induction of Egr-1 (data not shown). Whereas
reexpression of ERK2-wt or ERK2-D319N restored
Egr-1 expression, Egr-1 was significantly inhibited in
cells expressing ERK2-Y261A and was virtually unde-
tectable in the presence of ERK2-L198A/L232A (Figure
3C). These observations show for the first time that
ERK2 and DEF domain interactions are required for IEG
induction in vivo. Thus, specific signaling to DEF do-
mains plays a dual role of inducing IEG expression (Fig-Figure 3. Global ERK2 Signaling to DEF Domains Is Required for
Immediate Early Gene Induction
(A) Endogenous ERK1 and ERK2 were downregulated in HeLa cells
via siRNA, and the ability of the indicated HA-ERK2 alleles to signal
downstream to RSK was determined. Activation of transfected avian
RSK was assayed by measuring the activation-loop phosphoryla-
tion of the C-terminal RSK kinase domain with a phospho-T590-
specific antibody and by performing in vitro RSK kinase assays
(bar chart). The RSK activity remaining in ERK1/2 siRNA-trans-
fected cells was treated as background GST-S6 phosphorylation.
(B) Elk-1 transactivation in HeLa cells expressing the indicated
HA-ERK2 alleles was measured with a dual luciferase assay. Data
shown are the mean ± SEM of duplicate assays and are representa-
tive of three independent experiments.
(C) Endogenous ERK1 and ERK2 were downregulated with siRNAs,
and then ERK2 or the indicated mutants were reexpressed. Induc-
tion of the IEG Egr-1, only observed in the presence of ERK2-wt or
ERK2-D319N, was measured by Western blotting.ures 3B and 3C) and phosphorylating and activating
IEG products (Figure 2A).
Previous studies have revealed an important role for
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1322ERK1/2 in many cellular processes, including RNA g
csplicing, nucleotide biosynthesis, and cell migration,
survival, and proliferation. Although the kinetics of p
ERK1/2 signaling are important for generating signal
specificity [4, 20], additional molecular explanations of s
chow ERK1 and ERK2 regulate such processes are
needed. We show for the first time how distinct modu- z
ular-substrate interactions drive ERK1/2 specificity in
vivo. We used RNAi to downregulate endogenous ERK p
bsignaling before reexpressing various ERK mutants at
near-endogenous expression levels. In doing this, we a
shave functionally separated the ability of ERK1/2 to sig-
nal downstream via specific substrate docking sites. In m
saddition to the central role for DEF domains in the regu-
lation of IEG products [3], DEF-domain signaling is also w
prequired for IEG transcriptional induction. Therefore,
oncogenic Ras signaling uses DEF domains to drive ac- e
Itivation of IEGs as well as amplify IEG expression
through the DEF-dependent phosphorylation of gene t
dproducts during sustained or constitutive ERK signal-
ing. As shown in Figure 4, we predicted, on the basis p
iof the location of the DEF or D-domain binding pockets
on ERK2 [8, 9], that disrupting docking interactions m
swould not perturb kinase activity. Although the DEF-
domain binding region in ERK2 is proximal to its pTEpY h
Dactivation loop (Figure 4, residues in red) and hy-
drophobic stacking interactions exist between activa- q
ation-loop residue Y185 and the first aromatic residue in
DEF domains [8], mutation of this region does not pre-
Event ERK2 activation or functional signaling to D do-
mains in vivo. Furthermore, loss of DEF-domain signal-
Cing to nuclear targets was not due to defective spatial
H
regulation; ERK2 DEF-domain-interaction mutants lo- e
calized to the nucleus after growth-factor stimulation P
6as efficiently as wild-type ERK2. These findings sug-Figure 4. Molecular-Surface Representation of Activated ERK2 Docking Domains
ERK2 interacts with the D-domain substrate RSK through the CD domain (residues D316 and D319, colored green). The DEF docking domain
(residues M197, L198, Y231, L232, L235, and Y261, colored yellow) is necessary for interaction with and transactivation of the Ets family
transcription factor Elk-1. Importantly, DEF-domain interactions are also required for the induction and activation of immediate early genes
(IEGs) such as Egr1 and c-Fos. The dual phosphorylated activation loop of ERK2, pT183-E-pY185, is colored red. Surface representation of
activated rat ERK2 was created with PyMOL as described in the Experimental Procedures.est that the regulated nuclear translocation of ERK2
an occur independently of interactions with nucleo-
orin FXFG repeats.
Considerable attention has been directed toward
tudying the effect of inhibiting Ras signaling by using
ompetitive ATP analogs targeting the Raf and MEK en-
ymes. Indeed, small-molecule inhibitors are currently
nder clinical development [21, 22], but these com-
ounds may have significant toxicity due to global inhi-
ition of ERK1/2 signaling. Our observations suggest
n alternative strategy to inhibit oncogenic Ras/MAPK
ignaling. By mutating the substrate interaction do-
ains on ERK2, we have demonstrated that it is pos-
ible to terminate signaling to a subset of ERK effectors
ithout affecting ERK signaling to other targets. Im-
ortantly, because many cancers exhibit increased IEG
xpression, Ras/ERK-mediated phosphorylation of the
EG products is likely to be a pivotal step in controlling
umorigenicity [3, 4, 23, 24]. Intriguingly, the DEF-
omain binding pocket in the inactive ERK2 molecule is
artially occluded through intramolecular hydrophobic
nteractions, and upon ERK2 activation, extensive re-
odeling of the activation loop exposes the pocket for
ubstrate docking [8]. Thus, Ras-transformed cells that
ave constitutive ERK activation might be sensitized to
EF-domain inhibition. Additional studies will be re-
uired for evaluating the therapeutic potential of this
pproach.
xperimental Procedures
ell Lines and Treatments
eLa or NIH 3T3 cells were cultured in DME medium containing
ither 10% heat-inactivated FBS or 10% calf serum, respectively.
lasmid DNA transfections in HeLa and NIH 3T3 cells used Fugene
(Roche) and Lipofectamine 2000 (Invitrogen Corp., Carlsbad, CA),
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1323respectively, and Oligofectamine (Invitrogen Corp.) was used for
siRNA transfections. For ERK1/2 RNAi, HeLa cells were cultured
for 24 hr (90,000/35 mm dish) and then incubated with 50 nM siRNA
prepared with Oligofectamine and Optimem medium. Cells were
cultured in regular growth medium during the transfection period
(4 hr) and then re-fed with an equal volume of growth medium and
cultured for an additional 18 hr. Medium was then removed, cells
were washed with DME/20 mM HEPES, then incubated for 20 hr in
DME/20 mM HEPES prior to treatment with 50 ng/ml EGF (Invitro-
gen Corp.) and cell lysis. Reexpression of rat ERK2 in siRNA-trans-
fected cells was achieved by addition of HA-ERK/Fugene 6 com-
plexes to cells after the 4 hr siRNA transfection.
ERK1/2 Silencing
Two siRNA duplexes (Qiagen Inc., Valencia, CA) each for ERK1 and
ERK2 were included in transfections (50 nM final). The following











Mutagenesis, Kinase, Western, and Reporter Assays
Specific point mutations were introduced into rat HA-ERK2 with
the Quickchange kit (Stratagene), and sequences were verified. For
kinase assays, (His)6-FosEE (S374E/S362E) or GST-RSK-D2
(K464R) were used as substrates as described previously [4], and
where indicated, reactions included increasing concentrations of
the Elk-1 D-domain peptide QKGRKPRDLELPLSPSLL (D domain),
the DEF-domain peptide RRPRSPAKLSFTYPS, or the mutated
DEF-domain peptide RRPRSPAKLSATYPS [4]. Initial velocity ex-
periments measured phosphorylation of approximately 5 g of
substrate over time. The anti-phospho-T325 c-Fos antiserum was
used as described [4], the anti-phospho-S383 Elk-1 antibody was
from Biosource International (Camarillo, CA), and the anti-phos-
pho-T573 RSK antibody (recognizes pT590 in avian RSK) was from
R&D (Minneapolis, MN). Quantitation of Western blots was per-
formed with Quantity One software. HeLa cells were transfected
with GAL4-Elk-1 and GAL4-firefly luciferase [25] along with HA-
ERK2 constructs and pRL-tk renilla luciferase (Promega Corp.,
Madison, WI) and cultured for 18 hr prior to cells lysis and lucifer-
ase quantitation.
Immunofluorescence
HeLa cells were plated on poly-L lysine-coated glass coverslips
and transfected with siRNAs and HA-ERK2 alleles as described
above. Time-course analysis indicated that maximal ERK2 translo-
cation occurred after 5 min of EGF treatment. Anti-mouse Alexa594-
conjugated antibodies (Molecular Probes, Eugene, OR) were used
to visualize pERK1/2 and HA-ERK2 in situ. Images were captured
on a Nikon 80i upright microscope or a Nikon E800/Bio-Rad confo-
cal laser scanning microscope.
Surface Modeling of ERK2
The molecular-surface rendering of ERK2 was performed with rat
ppERK2 [26] and PyMOL software [27]. The pT183-E-pY185 activa-
tion loop is colored red. The CD domain is colored green and in-
cludes residues D316 and D319. Residues M197, L198, Y231, L232,
L235, and Y261 comprise the DEF docking domain and are col-
ored yellow.Supplemental Data
Two additional figures are provided with this manuscript online at
http://www.current-biology.com/cgi/content/full/15/14/1319/DC1/.
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